Tomoko Hamaya

Hirosaki University

Papers

4

Total Citations

62

H-Index

4

About

Dr. Tomoko Hamaya is a leading researcher in urologic oncology, with a focused expertise in the intersection of geriatric assessment and surgical outcomes for prostate cancer. Her work has been instrumental in establishing frailty—not just age—as a critical determinant of treatment suitability and postoperative recovery. Dr. Hamaya spearheaded the FRART-PC Study, which demonstrated that frailty and comorbidity significantly influence surgical contraindication in localized prostate cancer (19 citations). Through the FRAP Study, she provided the first prospective evidence that frailty is a predictor of moderate to severe pain after robot-assisted laparoscopic prostatectomy (17 citations). Her longitudinal FRARP-QL Study further showed that frailty directly impacts quality of life and lower urinary symptoms following surgery (12 citations). Additionally, her analysis of oncologic and patient-reported outcomes in men aged 75 and older (14 citations) challenges age-based treatment biases. By integrating geriatric assessment into surgical decision-making, Dr. Hamaya’s research empowers clinicians to personalize care for older patients, ensuring that frailty, not chronological age, guides treatment. Her work has profound implications for improving outcomes and quality of life in this growing patient population.

Research Focus

Key Achievements

4
H-Index
4
Papers
62
Total Citations
16
Avg Citations/Paper
🏆 Most Cited Paper
Effect of frailty and comorbidity on surgical contraindication in patients with localized prostate cancer (FRART-PC Study)
19 citations · 2020
📈 Most Prolific Year: 2020 (3 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Hirosaki University

Top Papers

  1. 1
  2. 2
  3. 3
  4. 4

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 13 days ago